The most effective medical treatment for acute ischaemic stroke (AIS) is to offer intravenous
thrombolysis during the ultra-early period of time after the onset. Even based on the …

Intracranial aneurysm is a common life-threatening disease. Computed tomography
angiography is recommended as the standard diagnosis tool; yet, interpretation can be time …

Introduction: Intravenous administration of tissue-type plasminogen activator (IV-tPA)
remains the only approved therapy that may reverse neurological deficit in patients with …

Objective: We sought to determine the safety of IV thrombolysis (IVT) in acute ischemic
stroke (AIS) patients harboring unruptured intracranial aneurysm (UIA) in a multicenter study …

Background Intracranial aneurysms are currently considered as contraindication for
intravenous thrombolysis in acute ischemic stroke, very likely due to a possible increase in …

Intravenous (IV) tissue plasminogen activator (tPA), which has convincing evidence in the
treatment of acute ischemic stroke, could not be used widely as desired despite the fact that …

Background For ischemic stroke patients with concomitant unruptured aneurysm,
intravenous thrombolysis therapy (IVT) remains a disputable decision. We hence performed …

Background The safety of antithrombotic therapy for patients with acute ischemic stroke
harboring unruptured intracranial aneurysms remains unclear. Aims This study was …

Background Management of ischemic stroke in the presence of aneurysmal brain disease is
controversial. Recent retrospective evidence suggests that in selected patients, intravenous …

Background The presence of an intracranial aneurysm is contraindicated to recombinant
tissue plasminogen activator (r-tPA) treatment for acute ischemic stroke. However, it is …